News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
Nurses freed from 240 hours of admin work yearly, patient care improves
Deloitte estimates automation could reclaim 13-21% of nurses' time annually. Health systems betting that less paperwork means better bedside presence and patient outcomes.
Parabilis raises $745M IPO for peptide drugs that cross cell membranes
Parabilis Medicines' upsized IPO and Regeneron partnership fund Helicon peptides designed to hit protein targets inside cells. Lead drug zolucatetide shows 74% response rate in desmoid tumors with no treatment discontinuations.
AstraZeneca bets $125M on ultrasound gene therapy as obesity drug expands
AstraZeneca is backing Sonothera with $125M to develop ultrasound-guided genetic medicine, while pushing its GLP-1 pill into late-stage trials. What the company sees in non-invasive gene delivery.
Parabilis raises $670M in largest biotech IPO yet, extending 2026 funding streak
Parabilis Therapeutics closed a record $670M IPO for a venture-backed biotech firm. Twelve drug startups have now raised $4.1B combined in 2026, signaling continued investor appetite for early-stage life sciences.
Sanofi halts immune disorder drug trial after latest setback
Sanofi stopped a late-stage trial for rilipubart, a therapy it had positioned as a potential blockbuster for chronic inflammatory demyelinating polyneuropathy. The failure marks another clinical disappointment for the pharma giant.
Ethyreal Bio raises $101M for thyroid eye disease treatment
Startup Ethyreal Bio closed a $101M funding round to develop a new medicine for thyroid eye disease and a related immune condition. Here's what the approach targets differently.
Takeda's $4B TYK2 drug beats Bristol Myers in psoriasis head-to-head
Takeda's zasocitinib outperformed Bristol Myers' Sotyktu in a direct trial, validating the company's long-held confidence in the drug's efficacy. What this means for the competitive psoriasis market.
Dexcom study backs glucose sensors for Type 2 diabetes without insulin
New clinical evidence could expand insurance coverage for Dexcom's continuous glucose monitors to Type 2 patients who don't use insulin injections.
Medtronic's Stealth AXiS surgical nav gets CE mark for ENT procedures in Europe
Medtronic's advanced surgical navigation platform Stealth AXiS has cleared CE marking for ear, nose, and throat procedures, expanding surgeon access across Europe.
MiniMed claims lead in fully closed-loop insulin systems without meal input
MiniMed's chief product officer says the company is "clearly ahead" in automated insulin delivery that removes the need for users to announce meals. What this means for the insulin pump market.
Bausch + Lomb cuts 119 jobs in Missouri plant restructuring
Bausch + Lomb is laying off 119 employees in Missouri by mid-December as part of a phased shift in manufacturing operations. The move signals ongoing consolidation in the ophthalmic device sector.
GT Medical raises $100M after brain tumor implant succeeds in trial
GT Medical secured $100M in funding following positive clinical trial results for GammaTile, an implantable radiotherapy device for brain tumors. The company says adoption is growing and the treatment is moving toward standard care.